Where Pfizer and Moderna vaccines will be produced in Europe
Ema has approved new production sites for BionTech-Pfizer and Moderna, up to 500 million more doses in 2021. Full details
The European Union tries to be prepared to face the second phase of the Covid-19 pandemic, that of coexistence with the virus . The vaccine remains the main weapon to counter the spread of the disease and the EMA is working to expand the number of producers of anti Covid-19 serums .
Vaccines for 70% of Europeans
"Our work to expand the production capacity of the European Union continues unabated". To say this in a tweet is the EU Commissioner for Health, Stella Kyriakides . “Six weeks ago we delivered enough sera to fully vaccinate 70% of European adults – continues the EU Commissioner -. Today Ema has approved new production sites for BionTech-Pfizer and Moderna, up to 500 million more doses in 202 1 ”.
Our work to expand
# COVID19 manufacturing capacity continues unabated. Six weeks ago we delivered enough vaccines to fully vaccinate 70% of
Today @EMA_News approves new manufacturing sites for #BionTech #Pfizer and #Moderna .
up to +500 million doses in 2021! https://t.co/SlmcDykIfO
– Stella Kyriakides (@SKyriakidesEU) August 24, 2021
The new French production site
Ema has approved an additional production site for the production of the anti Covid-19 vaccine developed by Pfizer. The plant is located in Saint Remy sur Avre, France, and is managed by Delpharm , a French pharmaceutical company that works exclusively for the development and production of medicines for third parties . The company was founded in 1988 in Tours, in the Loire, and over the years it has become a world leader in the production and development of outsourced medicines. On behalf of Pfizer and BionTech, it will produce 51 million doses of Comirnaty in 2021 .
BionTech's production expands
The EMA has also approved a new production line at the BioNTech factory located in Marburg , Germany. The integration of the new plant will allow the production capacity of the active ingredient to increase by approximately 410 million doses in 2021 .
Catalent will produce Spikevax
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved a new manufacturing site for Spikevax , the vaccine developed by Moderna. The facility is located in Bloomington , United States, and is operated by Catalent , a company that has been in business for 85 years and produces 70 billion doses of pharmaceuticals annually . The US company will produce the vaccine in its final formulation. The EMA Committee has also approved alternative sites responsible for testing, batch testing and packaging of the vaccine produced in the facility run by the Catalent company.
40 million more doses of Spikevax are coming from the US
Last July, the CHMP had already approved the increase in the production capacity of the active ingredient of the Moderna vaccine at two sites in the United States: Moderna TX, Inc., Norwood, Massachusetts and Lonza Biologics, Inc., Portsmouth, New Hampshire. These changes will allow 40 million more doses of Spikevax to reach the European Union market in the period September-December 2021.
Contract with Novavax for 100 million doses
In early August, the European Commission signed a contract with the American pharmaceutical company Novavax for the purchase of Covid-19 vaccines . The new vaccine, however, will first have to be reviewed and approved by the European Medicines Agency (EMA). If approval comes, member states will be able to purchase up to 100 million doses of the Novavax vaccine , with an option for 100 million additional doses over the course of 2021, 2022 and 2023. Health and Food Safety Commissioner Stella Kyriakides said Novavax is "another protein-based vaccine, a platform that is showing promise in clinical trials."
The third dose hypothesis
A third dose will most likely be needed to complete vaccine protection from Covid-19. “We are aware that a third dose of the vaccine may be needed – said Stefan De Keersmaecker , spokesman for the European Commission -. This is why we entered into an agreement with Pfizer , a short time ago, to ensure the necessary vaccine doses, for the third dose or for the vaccination of children. We follow the situation with the EMA , because all decisions must have scientific foundations ”.
This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/sanita/dove-saranno-prodotti-in-europa-i-vaccini-pfizer-e-moderna/ on Wed, 25 Aug 2021 12:55:24 +0000.